Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1/2 4Phase 1 3

Status

Completed 6Active not recruiting 5Recruiting 4Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Meningioma 1CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1Breast Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × capivasertib × Clear all
NCT02523014 2026-05-08

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
124 enrolled
CNS

Meningioma

NCT05593497 2026-03-27

SNARE

VA Office of Research and Development

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

GBG Forschungs GmbH

Phase 2 Recruiting
120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

National Taiwan University Hospital

Phase 2 Recruiting
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡